| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Cysteine protease falcipain-3 [5-492] |
|---|
| Ligand | BDBM50243232 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_491631 (CHEMBL945402) |
|---|
| IC50 | 21±n/a nM |
|---|
| Citation |  Verissimo, E; Berry, N; Gibbons, P; Cristiano, ML; Rosenthal, PJ; Gut, J; Ward, SA; O'Neill, PM Design and synthesis of novel 2-pyridone peptidomimetic falcipain 2/3 inhibitors. Bioorg Med Chem Lett18:4210-4 (2008) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Cysteine protease falcipain-3 [5-492] |
|---|
| Name: | Cysteine protease falcipain-3 [5-492] |
|---|
| Synonyms: | Cysteine protease falcipain-3 | Q9NAW4_PLAFA |
|---|
| Type: | PROTEIN |
|---|
| Mol. Mass.: | 56106.86 |
|---|
| Organism: | Plasmodium falciparum |
|---|
| Description: | ChEMBL_430127 |
|---|
| Residue: | 488 |
|---|
| Sequence: | MEYSPNEVIKQEREVFVGKEKSGSKFKRKRSIFIVLTVSICFMFALMLFYFTRNENNKTL
FTNSLSNNINDDYIINSLLKSESGKKFIVSKLEELISSYDKEKKMRTTGAEENNMNMNGI
DDKDNKSVSFVNKKNGNLKVNNNNQVSYSNLFDTKFLMDNLETVNLFYIFLKENNKKYET
SEEMQKRFIIFSENYRKIELHNKKTNSLYKRGMNKFGDLSPEEFRSKYLNLKTHGPFKTL
SPPVSYEANYEDVIKKYKPADAKLDRIAYDWRLHGGVTPVKDQALCGSCWAFSSVGSVES
QYAIRKKALFLFSEQELVDCSVKNNGCYGGYITNAFDDMIDLGGLCSQDDYPYVSNLPET
CNLKRCNERYTIKSYVSIPDDKFKEALRYLGPISISIAASDDFAFYRGGFYDGECGAAPN
HAVILVGYGMKDIYNEDTGRMEKFYYYIIKNSWGSDWGEGGYINLETDENGYKKTCSIGT
EAYVPLLE
|
|
|
|---|
| BDBM50243232 |
|---|
| n/a |
|---|
| Name | BDBM50243232 |
|---|
| Synonyms: | CHEMBL486232 | GNF-PF-5434 | N-((S)-4-methyl-1-oxo-1-((S)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-ylamino)pentan-2-yl)morpholine-4-carboxamide | N~2~-(MORPHOLIN-4-YLCARBONYL)-N~1~-[(1S,2E)-1-(2-PHENYLETHYL)-3-(PHENYLSULFONYL)PROP-2-ENYL]-D-LEUCINAMIDE |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C28H37N3O5S |
|---|
| Mol. Mass. | 527.675 |
|---|
| SMILES | CC(C)C[C@H](NC(=O)N1CCOCC1)C(=O)N[C@@H](CCc1ccccc1)C=CS(=O)(=O)c1ccccc1 |r,w:27.29| |
|---|
| Structure | 
|
|---|
Search and Browse
